Extra Corporeal Membrane Oxygenation Market is expected to register a CAGR of 3.6% during the forecast period, 2018 to 2023| Key Players - MEDTRONIC, INC., NIPRO, , ALUNG TECHNOLOGIES INC, LIVANOVA PLC, amongst others

Market Analysis:

North America to Dominate the Market
Extra corporeal membrane oxygenation market is for the patients that are suffering from both the heart failure and lung failure which acts as a cardiac and respiratory support. North America dominates the market due to the favorable reimbursement scenario and rising incidence of lung cancer in that region.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/16741
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

An ECMO machine works as a bypass for the heart and lungs which purifies the blood outside the human body. Cardiovascular diseases are the important cause of the death globally and many people die annually from the cardiovascular diseases than any other cause. According to the WHO 17.7 million people died from the cardiovascular disease which is around 31% of all global deaths and 7.4 million were due to coronary heart disease. In addition, technological advancement, rising incidence of the chronic obtrusive pulmonary disease (COPD) and increasing number of the cardiac surgeries are fuelling the growth of Global ECMO System Market. Various risks associated with ECMO machine and high cost of ECMO procedure are hindering the growth of Global ECMO system Market.

Request Discount on this report @ https://marketprognosis.com/discount-request/16741
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

Market Segments:
ECMO Market is segmented by:
1. APPLICATION: CARDIAC, RESPIRATORY, EXTRACORPOREAL CARDIOPULMONARY RESUSCITATION (ECPR)
2. MODALITY: VENO-ARTERIAL, VENO-VENOUS, ARTERIO-VENOUS
3. Geography: North America, South America, Europe, Asia Pacific, Middle East & Africa

Key Developments in the Market
• October, 2017: LivaNova Receives FDA Approvals for SenTiva Device and Next-Generation Vagus Nerve Stimulation (VNS) Therapy Programming System for Treatment of Epilepsy.
• July, 2017: Castor Branched Aortic Stent-Graft System receives approval from China Food and Drug Administration (CFDA) on 11 July 2017.

Enquiry Before Buying @ https://marketprognosis.com/enquiry/16741
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMarkPvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.